The experience of the use of denosumab in the treatment of patients with rheumatoid arthritis with osteoporosis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Therapy of rheumatoid arthritis (RA) is directed not only to suppress inflammation, but also to prevent the loss of bone mineral density (BMD). Denosumab, a promising and principally new drug for the treatment of secondary osteoporosis (OP), which reffers to the group of genetically engineered biological preparations and is a monoclonal antibody binding RANKL. As a result, the interaction of RANKL with its receptor is disturbed, which leads to a decrease in the activity of osteoclasts and a decrease in the resorption of bone tissue. The article presents the results of evaluation of the effect of densomab on the BMD of the axial and peripheral skeleton of RA patients with OP. It was shown that therapy with dosumab 60 mg subcutaneously 2 times a year with an interval of 6 months between injections allowed to significantly increase the BMD in the lumbar spine and the femoral neck, and also to stabilize the BMD in the distal forearm of RA patients with OP regardless of glucocorticosteroid intake.

Full Text

Restricted Access

About the authors

P. S Kovalenko

FSBIS “Scientific Research Institute of Rheumatology n.a. V.A. Nasonova"

Email: polina_dydykina@mail.ru
PhD, Junior Researcher at the Department of Metabolic Diseases of Joints and Bone Tissue

I. S Dydykina

FSBIS “Scientific Research Institute of Rheumatology n.a. V.A. Nasonova"

A. V Smirnov

FSBIS “Scientific Research Institute of Rheumatology n.a. V.A. Nasonova"

S. I Glukhova

FSBIS “Scientific Research Institute of Rheumatology n.a. V.A. Nasonova"

L. I Alekseeva

FSBIS “Scientific Research Institute of Rheumatology n.a. V.A. Nasonova"

E. L Nasonov

FSBIS “Scientific Research Institute of Rheumatology n.a. V.A. Nasonova"

References

  1. Насонов Е.Л., Насонова В.А. Ревматология. Национальное руководство. М., 2008. 290 с.
  2. Goldring S.R. Inflammation-induced bone loss in the rheumatic diseases. In Primer on metabolic bone disease and disorders of mineral metabolism. John Wiley and Sons, Inc, Hoboken 2009. Chapter 59.
  3. Насонов Е.Л., Скрипникова И.А., Насонова В.А. Проблема остеопороза в ревматологии. М., 1997. 429 с.
  4. Hofbauer L.C., Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004;292:490-95.
  5. Муравьев Ю.В., Дыдыкина И.С. Денситометрическая оценка МПК у больных РА. Клиническая ревматология. 1995;2:22-3.
  6. Celiker R., Gokce-Kutsal Y., Cindas A., Ariyurek M., Renda N., Koray Z., Basgoze O. Osteoporosis in rheumatoid arthritis: effect of disease activity. Clin. Rheumatol. 1995;14:429-33.
  7. Haugeberg G., Uhlig T., Flach J.A., Halse J.I., Kvien T.K. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis. Results from 394 patients in the Oslo country rheumatoid arthritis register. Arthritis Rheum. 2000;43:522-30.
  8. Kroger H., Honkanen R., Saarikoski S., Alhave E. Decreased axial BMD in perimenopausal women with rheumatoid arthritis - a population-based study. Ann. Rheum. Dis. 1994;53:18-23.
  9. Cortet B., Guyot M.H., Solau E., Pigny P., Dumoulin F., Flipo R.M. Factors influencing bone loss in rheumatoid arthritis: a longitudinal study. Clin. Exp. Rheumatol. 2000;18:683-90.
  10. Дыдыкина И.С., Дыдыкина П.С., Насонов Е.Л. Генно-инженерные биологические препараты в терапии остеопороза у больных ревматоидным артритом. «Остеопороз и остеопатии». Научно-практический журнал. 2013;2:12-9.
  11. Huusko T.M., Korpela M., Karppi P., Avikainen V., Kautiainen H., Sulkava R. Threefold increased risk of hip fracture with rheumatoid arthritis in Central Finland. Ann. Rheum. Dis. 2001; 60:521-22.
  12. Orstavik R.E., Haugeberg G., Uhlig T., Mowinckel P., Falch J.A., Halse J.I., Kvien T.K. Self-reported non-vertebral fractures in rheumatoid arthritis and population based controls: incidence and relationship with bone mineral density and clinical variables. Ann. Rheum. Dis. 2004;63:177-82.
  13. Van Staa P.P., Geusens P., Bijlsma J.W.J., Leufkens H.G.M., Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:3104-12.
  14. Подворотова М.М., Дыдыкина И.С., Таскина Е.А., Раскина Т.А., Королева М.А., Мурадянц А.А., Жугрова Е.С., Синенко А.А., Пешехонов Д.В., Сизиков А.Э., Ильина Н.А., Дыдыкина П.С., Петрова Е.В., Сороцкая В.Н., Большакова Т.Ю., Капустина Е.А., Виноградова И.Б., Алексеева Л.И., Смирнов А.В., Насонов Е.Л. Факторы риска переломов у больных ревматоидным артритом (предварительные результаты по материалам многоцентровой программы «Остеопороз при ревматоидном артрите: диагностика, факторы риска, переломы, лечение»). Научно-практическая ревматология. 2013;51(2):154-58.
  15. Kearns A.E., Khosla S., Kostenuik P.J. Receptor activator of nuclear factor kB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr. Rev. 2008;29:155-92.
  16. Cohen S.B., Dore R.K., Lane N.E., Ory P.A., Peterfy C.G., Sharp J.T., van der Heijde D., Zhou L., Tsuji W., Newmark R. Denosumab Treatment Effects on Structural Damage, Bone Mineral Density, and Bone Turnover in Rheumatoid Arthritis. A 12-month, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Clinical Trial. Arthritis Rheum. 2008;58(5):1299-309.
  17. Dore R.K., Cohen S.B., Lane N.E., Palmer W., Shergy W., Palmer W., Shergy W., Zhou L., Wang H., Tsuji W., Newmark R. Effects of denosumab on bone mineral density and bone turnover in patients with RA receiving concurrent glucocorticoids or bisphosphonates. Ann. Rheum. Dis. 2010;69:872-75.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies